Overweight and obesity: their relationship to metabolic syndrome, cardiovascular disease, and cancer in South America

Laura R Aballay, Aldo R Eynard, María del Pilar Díaz, Alicia Navarro, and Sonia E Muñoz

Socioeconomic and demographic transformations are occurring very rapidly in some areas of the world, especially in South America, and are accompanied by changes in lifestyle, dietary patterns, and the epidemiological profile of prevalent diseases. This review examines whether obesity and overweight are related to metabolic syndrome, cardiovascular disease, and cancer in South America. Research carried out in more than 6,000 cases and controls was evaluated, along with most of the available publications related to South America. In South America, obesity and risk factors for cardiovascular disease are related mainly to aging, ethnicity effects, and preventable risky lifestyle conditions. Most of the studies that found an association between cancer and obesity are from the Southern Cone, the geographic area most affected by this pathology. Overall, the prevalence of metabolic syndrome was highest in Chile, followed in decreasing order by Colombia, Peru, Argentina, and Ecuador, with differences noted between urban and rural areas or between urban and periurban areas. Obesity and cancer may be preventable, at least in part, by healthy behavior; hence, exercise, weight control, and healthy dietary habits are important to reduce the risk of these major chronic diseases.

INTRODUCTION

Obesity is a major public health concern worldwide, contributing to increased morbidity and mortality. It has emerged as a significant cause of diabetes, cardiovascular disease (CVD), and renal insufficiency. The accelerated worldwide increase of obesity prevalence has been named "globesity," with considerable variations observed between and within countries. Coincidentally, epidemiological patterns, food habits, and lifestyles are changing very fast.[1,2] Obesity affects both sexes and all ages, and, in Latin America, it increases with age and is always more prevalent in women, especially those from lower social strata.[3,4]

In recent decades, there has been an increase in chronic nontransmissible diseases (NTDs) in South America, associated with increased longevity and a decrease in infectious diseases.[5,6] Although the South American countries have different health profiles, CVD has become the leading cause of mortality in all of them, and metabolic syndrome (MetS) and cancer are also among the main causes of mortality.[5]

Studies about obesity in relation to other NTDs warrant special attention for several reasons. First, those affected by obesity and NTDs often share some unseen common causal factors, such as inappropriate eating habits and sedentarism. In addition, when obese people are identified, a high proportion of them are also found to

Affiliations: *LR Aballay, MP Díaz*, and *A Navarro are* with the Escuela de Nutrición, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina. *AR Eynard* and *SE Muñoz* are with the Instituto Biología Celular, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, and Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-CONICET), Argentina.

Correspondence: *SE Muñoz*, Instituto de Biología Celular, Enrique Barros esq. Enfermera Gordillo, Ciudad Universitaria, Córdoba C.P. 5000, Argentina. E-mail: smunoz@cmefcm.uncor.edu. Phone: +54-351-4629530/+54-351-4334021. Cell: +54-9-351-5211100. Fax: +54-351-4334021.

be at risk of other NTDs. Thus, by preventing obesity, most NTDs are prevented as well. Finally, when obesity is treated, the risks of complications diminish, thus reducing the effect of obesity on other risk factors.[7,8]

Similar to what has occurred in more developed societies, obesity is increasing in South America. However, the marked cultural, economic, and racial heterogeneity in the South American population generates conditions in which obesity, poverty, and malnutrition often coexist.[3,6]

LITERATURE SEARCH METHODS

A systematic literature search was conducted for the major sources of national and international surveys relating to obesity and overweight, MetS, CVD, and cancer. The search was restricted to articles published up to July 2011 for each South American country and to the adult population, although some consideration was given to obesity in childhood and adolescence.

GENERAL CONSIDERATIONS OF OBESITY

Obesity is a multifactorial disease caused mainly by the interaction of genetic and environmental factors.[9] The increase in body fat deposits generally coincides with an increase in body weight, leading to a greater risk of comorbidities and affecting both quality of life and life expectancy.[10] Adipose tissue plays a critical role in energy homeostasis in higher organisms. It serves as the main site for energy storage in the form of triglycerides (TGs), and it also contributes to systemic glucose and lipid metabolism via its function as an endocrine organ.[11]

The adipocyte, a highly differentiated cell from adipose tissue, synthesizes and releases a variety of substances that include tumor necrosis factor α (TNF-α), protein C, intercellular adhesion molecule, angiotensinogen, plasminogen activator inhibitor, adiponectin, and resistin, among others,[12] all of which fulfill different roles and are involved in the pathogenesis of chronic diseases. The discovery of leptin, melanocortin-4, and leptin receptors and the knowledge of hormonal mediator functions that participate in keeping correct body weight have enabled further understanding of the pathogenic processes and causes of obesity.[13]

Among the factors that contribute to the etiology of obesity, the genetic background inevitably overlaps with environmental factors as a necessary condition for the establishment of the disease. While the former probably sets the stage for obesity, the latter seems to determine the magnitude of the problem.[10,14,15] Even though differential characteristics can be observed in all South American countries, there are common aspects that include a dietary pattern with a higher caloric intake and a con-

comitant reduced nutrient density.[16] This implies an increase in the consumption of animal fat, added sugar, and refined foods, along with a decrease in the total intake of complex carbohydrates, fiber, fruits, and vegetables.[17–19] This leads to increased per capita caloric availability, coupled with a social environment in which little physical activity is likely. Hence, these are not single dietary changes but interrelated multifactorial processes, often involving modifications in sociocultural and economic conditions, individual behavior, and lifestyle.[20]

Some consideration should be given to obesity in childhood and adolescence as a predictor of this pathology in adults, and there are studies related to adolescents and adults in some South American countries. The Pan American Health Organization reports that, in Argentina, Colombia, Peru, Paraguay, and Uruguay, more than 15% of the entire population is obese. In Bolivia, Chile, Ecuador, and Peru, obesity in adolescent populations ranges between 11% and 15%, affecting a greater proportion of those in urban areas and of low socioeconomic status.[21–26]

National comparative studies found that the prevalence of obesity in the adult population is over 20% in 17 of 20 Latin American countries.[27] A summary of the data on the prevalence of overweight and obesity in South America (Table 1) shows that, in all South American countries except Brazil, Argentina, Colombia, and Bolivia, more than 50% of the population is overweight.[28–38] The countries with the highest prevalence of obesity are Chile, Trinidad and Tobago, and Paraguay, with the prevalence reaching 31% in Paraguay.[5] Other studies have been conducted in Uruguay and Argentina. In Uruguay, the Second National Survey of Overweight and Obesity in Adults showed overweight and obesity increasing linearly with age, with a sharp rise beginning at age 35 and reaching the highest levels after age 45.[39]

A recent population-based prevalence study (Córdoba Obesity and Diet Study) investigating the association of social and other factors with overweight and obesity in Argentina was conducted in a small- to medium-sized population with a sample size of 4,567 subjects in the years 2005–2006. The findings showed 52% of the subjects to be overweight and 17% to be obese.[6] The National Survey on Nutrition and Health, conducted in women in 2007, reported the prevalence of overweight to be 44.3% and that of obesity 19.4%.[28] Other available data derive from the general population of the cities of Venado Tuerto (Santa Fé province) and Dean Funes (Córdoba province), where the prevalence of overweight and obesity was found to be 59.3% and 62.6%, respectively.[40,41] In Argentina, one case-control study on dietary consumption and colon cancer showed that more than 40.0% of cases and 14.0% of controls were overweight and obese.[42]

Table 1 **Prevalence of obesity and overweight according to different South American national studies.**

Country	Overweight (%)	Preobesity (%)	Obesity (%)	Sex	Year	Reference
Argentina	44.3	24.9	19.4	Female	2004–2005	Ministerio de Salud, Presidencia de la Nación (2007)[28]
Brazil	40.60	29.5	11.1	Male and female	2003	Ministerio Saúde (2008)[29]
Bolivia	49.7	32.3	17.4	Female	2008	Ministerio de Salud y Deportes, Programa Reforma de Salud, and Instituto Nacional de Estadística (2009)[30]
Colombia	46.02	32.31	13.71	Male and female	2007	Rodriquez et al. (2009)[31]
Chile	59.7	37.8	21.9	Male and female	2003	Pérez et al. (1999)[32]
Ecuador	55	40.4	14.6	Female	2004	Centro de Estudios de Población y Desarrollo Social (2005)[33]
Peru	55.4	39.1	16.3	Male and female	2000	Instituto Cuánto (2000)[34]
Uruguay	52.4	35.4	17	Male and female	1998	Pisabarro et al. (2000)[35]
Guyana	51.4	29	22.4	Male and female	2003	Howard et al. (2003)[36]
Paraguay	69.5	37.9	31.6	Male and female	1991–1992	Figueredo (2001)[37]
Trinidad and Tobago	60	34	26	Male and female	2001	Ennis et al. (2003)[38]

No national studies were found for French Guyana, Venezuela, or Surinam.

The main comorbidities associated with obesity include MetS, CVD, and cancer, the magnitude and prevalence of which are increasing.[4] The next section reviews the main mechanisms involved in these diseases, along with the major epidemiological publications available in South America.

OBESITY AND COMORBIDITIES

Obesity and metabolic syndrome

Physiopathogeny. Obesity, especially abdomino-visceral, is associated with certain pathogenic factors that contribute to normal glucose homeostasis: high plasma levels of free fatty acids, increased hepatic glycogenesis, and peripheral insulin resistance.[43] In obesity, there is a chronic inflammatory state mediated by cytokines released by adipose tissue and by immune cells such as TNF-α, interleukin-6 (IL-6), plasminogen activator inhibitor, C-reactive protein, and resistin. This inflammatory background is not merely an undesirable by-product but a homeostatic mechanism to prevent the accumulation of excess fat. Lipid storage and weight increase require anabolic processes, while inflammation stimulates catabolism, including lipolysis. Homeostatic mechanisms, such as catabolism activation, via inflammation and resistance to anabolic signals, such as insulin, can be a way for the body to limit weight gain.[44–46]

As a consequence of chronic lipolysis, there is a continuous liberation of free fatty acids (fFAs) that are transferred directly, via the portal vein, to the liver. Increased plasma fFAs, together with inflammatory cytokines and lipoxins, trigger a decrease in insulin sensitivity in tissues that depend on insulin, which is caused by the inhibition of receptor signaling. This situation, known as insulin resistance (IR), leads to increased insulin synthesis and secretion by β pancreatic cells and, thus, to a compensatory hyperinsulinemia. Initially, the response may be able to maintain normal glucose homeostasis. Simultaneously, fFAs are oxidized in the liver, triggering neoglycogenesis and thus increasing glycemia. Concomitantly, there is an increase in the synthesis of very-low-density lipoproteins (VLDLs) that, once in the bloodstream, generate small, dense, and atherogenic low-density lipoproteins.[10,47–50]

Currently available data indicate that IR occurs mainly at the muscular postreceptor level, where 80% of circulating glucose is captured.[51] After a number of years, hyperinsulinemia can no longer compensate for this resistance. Consequently, the diminished muscular capacity for glucose uptake, added to a chronic, massive uptake of fFAs by the liver, results in an increase of hepatic gluconeogenesis to provide energy to the muscle and to avoid hepatic steatosis.

The process described is a landmark in the evolution of diabetes and is termed "prediabetes" or "glucose intolerance." The characteristics of prediabetes are part of the manifestations of Reaven's Syndrome X, now known as MetS, which, besides type 2 diabetes mellitus, or IR, or glycol intolerance, includes two of the following criteria: arterial hypertension, dyslipidemia, and abdominal obesity.[44,46,47,52] As a useful preventive measure, weight loss

diminishes insulin secretion by reducing IR, thereby reducing glucose intolerance.[53]

Glucose intolerance, when maintained longer than one or two decades, overloads the pancreas, resulting in a decline in insulin secretion due to the exhaustion of β cells.[54] These and other coexisting factors, such as genetic defects, insulin secretion interference, or increase of proinsulin, can lead to symptomatic diabetes mellitus. Finally, the main linking factor between chronic metabolic conditions (e.g., MetS) is IR, which is almost always associated with obesity, particularly abdominal-visceral obesity.[55]

Epidemiology of the metabolic syndrome in South America

MetS is a set of interrelated risk factors, including obesity, atherogenic dyslipidemia, arterial hypertension, and IR, which exponentially increase the risk of developing CVD and type 2 diabetes mellitus. There is little information published about the prevalence of chronic metabolic diseases in many Latin American countries. A cross-sectional, population-based, observational study (CARMELA) was conducted in Barquisimeto (Venezuela), Bogota (Colombia), Buenos Aires (Argentina), Lima (Peru), Mexico City (Mexico), Quito (Ecuador), and Santiago (Chile). The aim of the research was to study the prevalence of MetS in Latin America and its association with atherosclerosis.[56] Among the overall study population, the prevalence of diagnosed MetS was highest in Barquisimeto (26%), followed by Santiago (21%), Bogota (20%), Lima (18%), Buenos Aires (17%), and Quito (14%). When only nondiabetic participants were considered, prevalence followed a comparable ranking. Moreover, studies in Ecuador and Argentina showed that prevalence differed between urban and rural areas or between urban and periurban areas.[57,58]

Genetic load could be influencing the proneness to MetS onset. Indeed, a study comparing the risk factors for MetS among Afro-Hispanics and mixed Hispanics conducted in Zulia State (Venezuela) found higher blood pressure (BP), higher fasting blood glucose, more abdominal obesity, and lower HDL cholesterol among Afro-Hispanics.[59] Some early lifestyle factors may also influence MetS onset, leading to different patterns of CVD in the elderly and in rural areas.[60]

MetS also contributes heavily to the prevalence of CVD in Peru, where two studies found a higher prevalence of abdominal obesity coupled with MetS in women.[61] Abdominal obesity was also positively associated with MetS in a Chilean prevalence study, as were BP and plasma TGs.[62] Obesity was also related to MetS in Argentina,[63] Brazil,[64] and Trinidad and Tobago.[65] Finally, obesity and menopause are also associated with MetS,

perhaps linked to secondary hypoestrogenemia at the end of ovarian cycling.[66,67]

Obesity and cardiovascular disease

Physiopathogeny. The global epidemic of obesity is especially significant because obesity has been identified as the primary risk factor associated with the increased prevalence of CVD, diabetes, and hypertension.[9] The rates of CVD are known to be higher in overweight people. Although the mechanism of this association is not clear, there is considerable evidence relating it to an increase in cardiovascular risk factors.[10,45,68]

One of the metabolic alterations in obesity is the perturbation of lipoprotein metabolism and, in turn, the production of coronary atherosclerosis. Subjects with visceral obesity tend to have hypertriglyceridemia accompanied by low concentrations of high-density lipoprotein (HDL), which is the main factor responsible for poor scoring in total cholesterol/HDL cholesterol, a well-known powerful predictive risk parameter for coronary heart disease.[69–71]

Increased intra-abdominal fat is risky because adipocytes located in this area are metabolically very active and have intense lipogenesis and lipolysis.[72] In visceral adipose tissue, beta adrenergic-3 receptors predominate, and these are highly sensitive to the action of catecholamines. Catecholamines stimulate hormone-sensitive lipase, producing unbalanced lipolysis and hence the output of large amounts of fFAs into the portal circulation, with consequent liver overload.[73] Once fFAs are in the liver, the resynthesis of TGs, together with the overproduction of apolipoprotein B, results in the formation of increased amounts of VLDL, which is rich in TGs.[74] VLDL is degraded slowly, due to the decreased activity of lipoprotein lipase as a result of IR/hyperinsulinemia, which is very often present in individuals with visceral obesity.[74]

The alteration in the metabolism of VLDL causes reduced availability of substrates for the formation of HDL, which leads to the formation of highly atherogenic low-density lipoprotein, which then easily crosses the arterial endothelium, thereby starting the atherosclerotic process.[73] Therefore, the abnormalities produced during the metabolism of lipoproteins in subjects with visceral obesity determine the presence of the "atherogenic triad" (increased TG-rich VLDL, low amounts of HDL, and high levels of low-density lipoprotein).[67] Eventually, these abnormalities lead to atherosclerosis of the coronary arteries and the onset of coronary heart disease.[75–78]

Arterial hypertension is a cardiovascular condition that merits special attention, and thus it is discussed further in the following paragraphs.

Arterial hypertension. Weight gain can induce a significant increase in BP, and some studies have shown higher BP values in obese or preobese populations.[79,80] In normotensive and hypertensive subjects, there is a positive correlation between body mass index and BP.[81] However, not all overweight or obese people are hypertensive, which may be explained by a genetic difference in BP response to weight gain.[47,51,81]

In obese people, inflammation, the common response of the body to tissue injury, becomes chronic. Inflammatory messengers are released by stressed adipocytes and, over the course of time, inflammatory cells cause vascular damage, leading to atherosclerotic phenomena. Eventually, these perturbations lead to severe problems such as ischemic heart disease, renal insufficiency, and blindness.[82]

Approximately 50% of obese people develop arterial hypertension at some point.[83] The mechanisms involved are multiple. One is hyperinsulinemia, which results in increased reabsorption of sodium (Na^+) and water. In addition, in the obese, the activity of the sympathetic nervous system (SNS) increases with meals, often resulting in hyperinsulinemia and hyperleptinemia. Moreover, this increased activity counteracts arteriolar vasodilatation, causes the release of angiotensinogen, and disturbs nitric oxide (NO) bioactivity. The presence of arterial hypertension in obese subjects often coincides with the presence of lipid abnormalities, adding the risk of vascular alterations.[84,85]

There is a worldwide agreement that an increase in physical activity prevents obesity and that regular exercise provides many health benefits. A sedentary lifestyle is the primary cause of obesity, one of the main risk factors for MetS, CVD, and cancer. Recent studies from Argentina, Chile, and Brazil show that this seems also the case for South America.[6,86,87] The Argentinean study showed that overweight was strongly dependent on gender, age, social status, and physical activity. Moderate and intense physical activity (>1,500 standard metabolic equivalent units [METs]) reduces the risk of obesity by around 40–65%.[6,87] As suggested by Das,[88] exercise attenuates the development of risk factors for arterial hypertension and CVD by increasing the number of NO-positive neurons, as shown in spontaneously hypertensive rats, and by exerting an anti-inflammatory effect.

Hausberg et al.[89] proposed an explanation of the association between overweight, obesity, and hypertension from a physiological point of view. With higher caloric intake or reduced thermogenesis, subjects tend to progress towards overweight or obesity. As a response, the body tries to burn calories, thereby stimulating thermogenesis, which requires activation of the SNS. These processes cause vascular constriction, elevated heart rate, and increased cardiac output. The increase in cardiac output coupled with the rise in peripheral resistance leads to a hypertensive effect. In addition, insulin stimulates the activity of the SNS, worsening the situation. Hyperinsulinemia, which results from the strength of the effects of insulin on glucose uptake, increases sympathetic activity, which facilitates the increase in BP. SNS activity and the increase in circulating insulin may increase sodium reabsorption in the kidney, thus increasing BP. This is called salt sensitivity. Weight loss improves renal sodium handling by decreasing sympathetic activity, potentially allowing hyperinsulinemia, salt sensitivity, and hypertension to be reversed.[78,81]

Adipose tissue is an essential, complex, metabolically active tissue with central endocrine functions. Fat cells actively regulate the pathways responsible for energy balance through a complex network of hormonal and neural signals and chemical messengers such as TNF-α, angiotensinogen, and leptin complex.[90,91] TNF-α stimulates production of angiotensinogen and angiotensin II, among others. Chronic exposure of tissues to elevated insulin levels leads to activation of the renin-angiotensin system through TNF-α, favoring increased BP.[44,81]

All components of the renin-angiotensin system are present in different tissues, including adipose tissue, and may be linked to obesity and arterial hypertension.[83] Adipose tissue produces several proteins of the renin-angiotensin system in increased amounts, including angiotensin II.[10] Abdominal fat cells release angiotensin with greater intensity than subcutaneous fat tissues. Hence leptin, an adipocytokine with receptors in the hypothalamus, has been proposed as a link between obesity and elevated SNS activity and can be considered one of the major factors in the development of obesity-associated arterial hypertension.[91]

Epidemiology of cardiovascular disease

Even though CVD is a major cause of death in South America and obesity is the prevalent risk factor for CVD, published research on CVD and obesity is still scarce.[92] The rates of CVD range from 9% in Ecuador to more than 34% in the countries of the Southern Cone.[93] A recent study describing CVD mortality trends in the Americas during 1970–2000 found a decrease in coronary heart disease mortality for Argentina, Brazil, and Chile. Mortality rates among men were highest in Venezuela and lowest in Argentina. In women, rates were highest in Cuba and lowest in Argentina.[94]

The Andean region. Several published works analyze the association of obesity and/or anthropometric parameters as indicators of ischemic coronary disease in Andean South America. The main findings show a positive association between high anthropometric indicators for

waist-to-hip index and body mass index in men, with obesity being an important risk factor for ischemic coronary disease.[95] The five most prevalent cardiometabolic factors were low HDL, overweight/obesity, abdominal obesity, hypercholesterolemia, and IR. MetS was most prevalent among women.[96]

Some authors point out the importance of interethnic differences, especially for men.[97,98] Indeed, the sociocultural context alters the risk for obesity and CVD associated with individual-level variables and accounts for gender and cross-national differences in the migration-illness association.[99] Not only international cross-border migrations but also intranational migrations of different ethnic groups change the risk of obesity and associated disorders as well.[100]

Tropical and subtropical regions. CVD causes approximately 30% of all deaths in Brazil. Of these, approximately 50% occur in adults aged 30–69 years. Central obesity, physical inactivity, and unhealthy diet were all inversely associated with income and schooling and were found at higher levels in subjects aged 50–59 years, without significant differences between sexes.[101] A follow-up study showed that the BP of young individuals was significantly associated with cardiovascular risk variables such as glucose levels, TGs, total cholesterol and its fractions, waist-to-hip ratio, and the occurrence of MetS at the young adult stage.[102] Obesity and overweight and other lifestyle conditions are strong risk factors for CVD in Brazil, even when the distinct characteristics within the country's great geographical size, the urban and rural heterogeneities, and the ethnic differences in the population are taken into account.[103,104]

In contrast, in Trinidad and Tobago, differences in morbidity and mortality are attributable to ethnicity. Individuals from these two Caribbean islands have different genetic backgrounds and lifestyles. While Tobago is a peaceful tourist center, Trinidad has a comparatively bustling lifestyle. Generalized (31.7% versus 38.8%) and central (78.5% versus 83.7%) obesity are similar in both islands, but islanders from Trinidad have a greater risk of CVD.[65] Another study conducted in both islands found that body mass index, abdominal obesity, and diabetes were all associated with increased systolic BP.[105]

The temperate countries of the Southern Cone. The prevalence of CVD is highest in the Southern Cone, where it is approximately 34% among the entire population. In a well-controlled survey carried out in the adult general population of Uruguay, obesity was significantly associated with hypertension, and both conditions were independent risk factors for CVD.[106]

Stroke and CVD are also major causes of death in Paraguay.[81] In a cross-sectional study conducted in an urban white-Hispanic population, the prevalence of obesity was 31.6% and was greater in women. Subjects with impaired glucose tolerance had cardiovascular risk factors significantly more often than the normal population.[107,108]

In 2005, the Argentine National Health Ministry conducted a survey of risk factors for NTDs in adults ≥18 years of age to determine the prevalence of risk factors for chronic disease. The sample represented 96% of adults living in urban areas. Low income and poor education were associated with increased risk of hypertension and diabetes in all subjects, and with obesity in women. The habit of eating fruits and vegetables 5 days per week was positively associated with higher income.[109] The burden of CVD was associated with modifiable and, therefore, preventable lifestyle risk factors.[110] This cross-sectional study of a major urban area provides some insight into the global transition toward concentrations of risk factors in poorer populations.[109]

An observational prospective cohort study to identify CVD risk factors is being conducted in the Southern Cone region to develop public health strategies.[111] All of these findings, however, confirm that obesity and other risk factors for CVD in South America are mainly related to aging, ethnicity effects, and preventable risky lifestyle conditions.

Obesity and cancer

Many studies have shown that obesity is a risk factor for diabetes, but a link between obesity and cancer is generally less widely reported. Some works, however, have confirmed that obesity may be associated with mortality from a number of malignancies, including cancers of the colon, pancreas, kidney, prostate, breast, and endometrium.[112] Evidence suggests that the link between obesity and cancer may involve metabolic perturbations similar to those shown to exist between obesity and diabetes.[113]

Pathogenesis. Like obesity, cancer is a multifactorial disease of aging in which race and inheritance are recognized as genetic determinants of risk, which varies according to different localizations. On the other hand, diet, toxic habits, lifestyle, and environment, including infections, are factors that act on the cell genome as initiators or promoters of malignant cell transformation and progression.[114–117]

The association between viral, bacterial, or chemical inflammation and different cancers strongly suggests that chronic inflammation may be involved in the development of tumors.[118–120] Clinical and epidemiological studies have suggested a strong association between chronic infection, inflammation, and cancer.[120–124] As stated by Das in 2007,[125] inflammation is a protective response in order to eliminate the injury-inducing agent,

prevent tissue damage, and initiate the repair process. Among the inflammation mediators are histamine, serotonin, lysosomal enzymes, prostaglandins, leukotrienes, lipoxins, platelet-activating factors, reactive oxygen species, NO, hypochlorite, and various cytokines, along with the kinin, the coagulation-fibrinolysis, and the complement systems. Once released or activated, most of these mediators decay quickly or are inactivated, suggesting that, under normal physiological conditions, there are both positive and negative checks and balances. When a continuous imbalance occurs, a pathological event, such as cancer, may appear.[126]

Chronic inflammation is considered a common feature of MetS and age-associated neuroendocrine disorders (MetS/AAND).[125,126] Oxenkrug[127] suggests that one of the mechanisms by which chronic inflammation might trigger and/or maintain the development of MetS/AAND is transcriptional induction via certain cytokines. Cytokines are low-molecular-weight peptides, essential for cell communication, which are produced mainly by cells that belong to the immune system. Cytokines control several key cell functions, such as differentiation, inflammation, local or systemic immune response, tissue repair, hematopoiesis, apoptosis, and regulation of energy intake and expenditure.[128] They can also play a role in the control of tumor cells (transforming growth factor β). Cytokines are apparently redundant and pleiotropic; as a result, they can share functions and act on many cell types, since a cell can have receptors for more than one cytokine. Alternatively, they may act as paired agonist/antagonist ligands in several cell functions[129,130]

Since proinflammatory cytokines influence tumor microenvironment, promote cell growth and survival, and angiogenesis, tumor cell is facilitated.[131] It has been suggested that one of the mechanisms is transcriptional induction of indoleamine 2,3-dioxygenase, a rate-limiting enzyme of the tryptophan-kynurenine pathway.[132] This process is mediated by proinflammatory cytokines whose induction may activate tryptophan metabolism for kynurenine formation.[133–135] Kynurenines are immune mediators that may contribute to MetS/AAND via their apoptotic, neurotoxic, and pro-oxidative effects and their upregulation of inducible NO synthase, phospholipase A2, arachidonic acid, prostaglandin, 5-lipoxygenase, leukotriene, and other eicosanoid cascades. All of these molecules play key roles in neoplasia.[130,132]

According to Karin and Greten,[133,134] one of the links between inflammation and tumorigenesis is provided by inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) kinase signaling pathway. NF-κB, a transcription factor that mediates the transcription of a vast array of proteins involved in cell survival and proliferation, is itself activated by many proinflammatory cytokines. Indeed, it has recently been

shown that proinflammatory cytokines (TNF-α, also called cachexin or cachectin, and interleukin 1) can activate a novel transcriptional mechanism by which estrogen receptors and NF-κB cooperate to upregulate the expression of ATP-binding cassette transporter G2. This molecule is a transmembrane transporter that plays a key role in the response to therapeutic drugs in breast cancer cells.[135,136]

In short, the whole outcome of a persistent inflammatory microenvironment is enhanced tumor promotion, accelerated tumor progression, invasion of the surrounding tissues, angiogenesis, and, often, collaboration toward a suitable tumor bed for metastasis.[122,124,133,135]

Obesity is a low-inflammation state in which cytokine production from visceral adipose tissue (adipocytokines) increases, which causes endothelial dysfunction and IR.[128] This low-grade inflammatory process is defined as a two- to-four-fold rise in circulating levels of 1) proinflammatory and anti-inflammatory cytokines, 2) naturally occurring cytokine antagonists, and 3) acute-phase inflammatory proteins, as well as minor increases in counts of neutrophils and natural killer cells.[124,137,138] High levels of two inflammation markers, butyrylcholinesterase and acetylcholinesterase, may be included in this scenario.[125]

Adipocytokines are the cytokines produced by adipose tissue. They include leptin, adiponectin, resistin, visfatin, retinol binding protein (RBP) 4, angiotensinogen, TNF-α, plasminogen activator inhibitor 1, interleukin (IL) 1, IL-6. IL-8, adipsin, several polyunsaturated fatty acids and derivatives, sex steroids, different growth factors, serum amyloid, and lipocalcin, among others. Adipocytokines act synergistically or competitively with insulin, which explains their modulatory role in IR. Inflammatory cytokines from adipose tissue could affect blood vessel endothelial function even without increases in plasma concentrations.[139]

Leptin participates in many diverse physiological processes, such as reproduction, immunity, and angiogenesis. Angiogenesis is one of the conditions necessary for tumoral progression.[140] On the other hand, adiponectin improves insulin sensitivity and inhibits vascular inflammation. One of its functions is autocrine inhibition of endoplasmic synthesis of proinflammatory adipokines.[141]

TNF-α is one of the most powerful inflammatory adipokines. It stimulates the acute phase reaction of inflammation. The primary role of TNF is the regulation of immune cells. TNF is also able to induce apoptotic cell death, suppress appetite (thus the reason it is also called cachectin), and inhibit tumorigenesis and viral replication. Dysregulation of TNF production has been implicated in a variety of human diseases such as cancer, IR, and adiposity.[136,142]

IL-6, an adipokine, is a multifunctional cytokine that was originally characterized as a regulator of specific immune and inflammatory responses. IL-6 inhibits insulin 2 receptor, lipogenesis, and adipokine synthesis. Elevated expression of IL-6 has been detected in breast and lung tumors.[138,143,144] It has also been related to cancers of the liver,[145] cervix,[146] prostate,[147–150] and breast.[151]

Other authors suggest that the link between obesity and cancer is mainly due to IR. The link between IR and cancer may be related to high compensatory levels of insulin. This hormone may increase cell proliferation either directly[152,153] or by increasing the levels of other more potent growth factors, such as insulin-like growth factor, which is one of the growth factors responsible for the initial steps of cancer development. However, evidence that IR is the major cause of increased risk of cancer, other than colon cancer, is still inconsistent.

In diet-induced obesity, hypothalamic inflammation is triggered as an outcome of prolonged exposure to diets high in fat and/or sugar.[154] Saturated fatty acids can induce endoplasmic reticulum stress in the hypothalamus tissue. On the other hand, there is evidence that polyunsaturated fatty acids, such as gamma-linolenic acid, may inhibit tumor growth due to the production of lipid peroxides, apoptosis, and lipoxygenase-derived eicosanoids.[155] Hence, obesity may promote carcinogenesis because it shares some metabolic pathways of inflammation with carcinogenesis.

Epidemiology of cancer in South America. Epidemiological studies indicate that overweight and obesity, along with diet and lifestyle, contribute to the risk for some cancers. In countries where people have adopted so-called "Western diets," the incidence of tumors, particularly those of diet-related cancers, is increasing. This trend in developing countries is associated with increased consumption of fatty and/or sugary foods and decreased physical activity, resulting in obesity.[156]

In South America, the five most incident cancers in men are prostate, lung, stomach, colorectal, and bladder, while in women these are breast, uterine cervical, colorectal, stomach, and lung.[157] Cancer is the second-leading cause of mortality after CVD in half of the South American countries, i.e., Uruguay, Argentina,[158–164] Chile, Peru, Trinidad and Tobago, Bolivia, and Venezuela.[157] However, only a few works assessing the relationship between obesity/overweight and cancer have been published in this subcontinent.

The increase in cancer and obesity in the temperate region that includes Argentina, Chile, Uruguay, and Southern Brazil probably reflects the adoption of Western behaviors and lifestyles in parallel with the alluvial European immigration of the last half of the 19th century and the beginning of the 20th century.[165] Moreover, the temperate regions have lately experienced a rapid agricultural evolution, and rural areas have undergone a significant economic transition.[166] In these areas, people have a high-fat diet, a low average fertility rate, and a higher socioeconomic status, and the influence of European immigration on the genetic background of the population is more pronounced.[167] Argentina and Uruguay are also characterized by their traditional high consumption of beef, which corresponds to a high intake of total and saturated fats.[28,167–172] In Chile, the progressive improvement of social conditions has generated an important economic and epidemiological transition, and morbimortality patterns are changing in terms of chronic NTDs. Since the 1980s, CVD and tumors are the main causes of mortality in Chile.[173] Brazil traditionally consumes large quantities of poultry, legumes, and fruits. However, with their technological and economic improvement, there has been an increased production and consumption of red meats. As a consequence, the studies relating to cancer and obesity come mainly from Argentina, Brazil, Chile, and Uruguay, the members of the so-called Southern Cone.

A number of studies in South America have investigated different type of cancers and their association with obesity, including breast, prostate, colon, and urinary tract tumors and endometrial cancers. Breast cancer is the most common cancer in women worldwide. Several studies have been conducted in Chile, Uruguay, and Argentina. A case-control study performed in Chile to analyze the association between food patterns, obesity, and breast cancer revealed that obesity was a risk factor, independently of the differences in food patterns.[174] A case-control study carried out in Uruguay showed that an endomorphic body type was significantly associated with breast cancer, regardless of menopausal status or BMI level.[175] The authors found that fat fraction and fat-to-muscle ratio were both positively associated with breast cancer.[175,176] No association between overweight and breast cancer was found in Argentina, although a significantly higher caloric intake was found among cases.[177] A comparative study of breast cancer in countries with different incidence rates suggests that reproductive events and body fat may exert similar effects on all women, due to similarities of parameter estimates across the region, regardless of breast cancer rates in their country of residence.[178]

Prostate cancer is the second most common cancer in men worldwide, and it also ranks second in men in South America.[179] Obesity, central adiposity, and several dietary factors have been suggested as risk factors. Although obesity has been positively associated with prostate cancer, López Fontana et al.[180] suggest that obesity may promote the progression of established prostate cancer rather than being a risk factor. In work carried

out in Puerto Rico in which Hispanics were compared with white people, overweight was a less sensitive marker for prostate cancer in Hispanics, but the prevalence of metastasis was higher in individuals with a higher body mass index.[181]

Globally, colorectal cancer is the third-leading cause of cancer in males and the fourth-leading cause of cancer in females. The frequency of colorectal cancer varies around the world. It is common in the Western world and is rare in Asia and Africa. In countries where people have adopted Western diets, the incidence of colorectal cancer is increasing. Argentina, in the central temperate region of South America, has important ethnic and geographical variations and was a suitable setting for case-control studies into the risk of cancer in relation to diet and other lifestyle factors.[182,183] Several studies produced original data on colorectal cancer[42,167–171] and urinary tract tumors.[184,185] In these studies, most patients were overweight to some extent, although there were no significant differences between cases and controls. Interestingly, the Western dietary pattern of high energy intake, sweet foods and beverages, fatty meats, potatoes, alcohol, and low fiber intake was associated with cases.

Obesity has also been related to endometrial cancer. In a Chilean study of the effect of obesity on endometrial cell proliferation, the authors showed a correlation between obesity and overweight and increased endometrial cell proliferation as a possible factor related to the higher risk of developing type I endometrial cancer in overweight and obese women.[186]

Three of the nine most common cancers – breast, prostate, and colon – have already been associated with obesity in South America. Obesity and cancer predominate in the temperate region of South America. This pattern coincides with a period of greater industrialization, and therefore a possible exposure to other contaminants may exist, suggesting that, unfortunately, in a few years other countries such as Bolivia and Paraguay may also appear in this worrying scenario.

CONCLUSION

Those countries in South America whose ethnicity changed due to waves of immigrants in the middle of the 19th and beginning of the 20th centuries, like Argentina, Brazil, Trinidad and Tobago, Uruguay, and, to a lesser extent, Chile, show a pattern of dietary habits and lifestyle that is progressively closer to that of the so-called "Western lifestyle." Diseases closely related to environment and lifestyle, such as diabetes, obesity, cancer, and CVD, have been rapidly increasing in these countries over the last five decades. In contrast, in other South American countries where ancient, healthy, nutritional habits and dietary behaviors are still maintained, the prevalence of such chronic and partly avoidable diseases is lower. Some risks, such as high waist-to-hip index, low income, and poor education, are common. Many Hispanic immigrants in the United States and Western Europe originate from South America. Although the incidence and frequency of these diseases may change over one or two generations, a starting point to prevent these illnesses in other parts of the world would be to conduct epidemiological studies in the countries of origin of Latin-American populations, including studies on the role of ethnicity. Taken together, the data presented in this overview indicate that measures to prevent diet- and lifestyle-related diseases are imperative in South America and should include education in nutrition, health, and lifestyle habits.

REFERENCES

1. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804–814.
2. Drewnowski A, Popkin BM. The nutrition transition: new trends in the global diet. Nutr Rev. 1997;55:31–43.
3. Popkin BM. The nutrition transition in low-income countries: an emerging crisis. Nutr Rev. 1994;52:285–298.
4. Montero JC. Epidemiología de la obesidad en siete países de América Latina [in Spanish]. Form Contin Nutr Obes. 2002;5:325–330.
5. World Health Organization. *The Global Health Observatory*. 2012; Available at: http://www.who.int/gho/en/index.html. Accessed 9 November 2012.
6. Aballay LR, Osella AR, Celi A, et al. Overweight and obesity: prevalence and their association with some social characteristics in a random sample population-based study in Córdoba city, Argentina. Obes Res Clin Pract. 2009;3:75–83.
7. Albala C, Vio F, Kain J, et al. Nutrition transition in Latin America: the case of Chile. Nutr Rev. 2001;59:170–176.
8. Peña M, Bacallao J. La obesidad y sus tendencias en la región [in Spanish]. Rev Panam Salud Publica. 2001;10:75–78.
9. Mathes WF, Kelly SA, Pomp D. Advances in comparative genetics: influence of genetics on obesity. Br J Nutr. 2011;106(Suppl 1):S1–S10.
10. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults*. Report No. 98-4083. Bethesda, MD: National Heart, Lung, and Blood Institute; 1998. Available at: http://www.ncbi.nlm.nih.gov/books/NBK2003/. Accessed 18 October 2012.
11. Fernández Real JM, Catalán V, Moreno Navarrete JM, et al. Study of caveolin-1 gene expression in whole adipose tissue and its subfractions and during differentiation of human adipocytes. Nutr Metab. 2010;7:1–9.
12. Guerrero-Millo M. Adipose tissue hormones. J Endocrinol. 2002;25:855–861.
13. Booth ML, Chey T, Wake M, et al. Change in the prevalence of overweight and obesity among young Australians, 1969–1997. Am J Clin Nutr. 2003;77:29–36.
14. Dyer JS, Rosenfeld CR. Metabolic imprinting by prenatal, perinatal, and postnatal overnutrition: a review. Semin Reprod Med. 2011;29:266–276.
15. Cummings DE, Schwartz MW. Genetics and pathophysiology of human obesity. Annu Rev Med. 2003;54:453–471.
16. Barría RM, Amigo H. Nutrition transition: a review of Latin American profile. Arch Latinoam Nutr. 2006;56:3–11.

17. Popkin BM. Nutrition transition and obesity in the developing world. J Nutr. 2001;131:S881–S886.

18. Organización Mundial de la Salud. *Dieta, nutrición y prevención de enfermedades crónicas* [in Spanish]. 2003; Available at: ftp://ftp.fao.org/docrep/fao/006/ac911s/ac911s00.pdf. Accessed 31 October 2012.

19. Monteiro C. La Transición Epidemiológica en el Brasil. In: Peña M, Bacallao J, eds. *La Obesidad en la Pobreza: un nuevo reto para la salud pública* [in Spanish]. Washington, DC: Organización Panamericana de la Salud, Publicación científica N°576; 2000:73–83.

20. López de Blanco M, Carmona A. La Transición alimentaria y nutricional: un reto en el siglo XXI [in Spanish]. An Venez Nutr. 2005;18:90–104.

21. Roca L, Mejía Salas H. Prevalence and risk factors associated with obesity and overweight. Rev Soc Bol Ped. 2008;47:8–12.

22. Yepes R. La obesidad en el Ecuador en tempranas edades de la vida [in Spanish]. Rev Fac Ciencias Médicas. 2005;30:20–24.

23. Organización Mundial de la Salud. *Régimen alimentario, nutrición y actividad física* [in Spanish]. 2004; Available at: http://www.who.int/dietphysicalactivity/strategy/eb11344/strategy_spanish_web.pdf . Accessed 31 October 2012.

24. Castro Burbano J, Fornasini M, Acosta M. Prevalence and risk factors for overweight among school girls 12 to 19 years old in a semi-urban region of Ecuador. Rev Panam Salud Publica. 2003;13:277–284.

25. Yepez R, Carrasco F, Baldeon ME. Prevalencia de sobrepeso y obesidad en estudiantes adolescentes ecuatorianos del área urbana [in Spanish]. Arch Latinoam Nutr. 2008;58:139–143.

26. Kovalskys I, Bay L, Herscovci C, et al. Prevalencia de obesidad en una población de 10 a 19 años en la consulta pediátrica [in Spanish]. Arch Argent Pediatr. 2003; 101:441–447.

27. Filozof C, Gonzalez C, Sereday M, et al. Obesity prevalence and trends in Latin-American countries. Obes Rev. 2001;2:99–106.

28. Ministerio de Salud, Presidencia de la Nación. *Encuesta Nacional de Nutrición y Salud* [in Spanish]. 2007; Available at: http://msal.gov.ar/htm/Site/ennys/pdf/ENNyS_Documento-de-resultados-2007-II.pdf%20. Accessed 9 November 2012.

29. Ministerio de Saúde. *Pesquisa Nacional de Demografia e Saúde da Crianza e da Mulher – PNDS 2006 – Final Report* [in Portuguese]. Brasilia: Ministerio da Saúde; 2008.

30. Ministerio de Salud y Deportes, Programa Reforma de Salud, and Instituto Nacional de Estadística. *Encuesta Nacional de Demografía y Salud ENDSA 2008 [in Spanish]*. Calverton, MD: Macro International; 2009.

31. Rodriquez J, Ruiz F, Peñaloza E, et al. *Encuesta Nacional de Salud 2007. Resultados Nacionales* [in Spanish]. Bogotá, Colombia: Ministerio de la Protección Social; 2009.

32. Pérez F, Carrasco E, Santos JL, et al. Prevalencia de obesidad, hipertensión arterial y dislipidemia en grupos aborígenes rurales de Chile [in Spanish]. Rev Med Chil. 1999;127:1169–1175.

33. Centro de Estudios de Población y Desarrollo Social (CEPAR). *Encuesta Demográfica y de Salud Materna e Infantil 2004* [in Spanish]. Quito, Ecuador: Centro de Estudios de Población y Desarrollo Social (CEPAR); 2005.

34. Instituto Cuánto. Peru National Living Standards Measurement Survey 2000. Lima, Peru: Instituto Cuánto. Available at: http://www.healthmetricsandevaluation.org/ghdx/record/peru-national-living-standards-measurement-survey-2000. Accessed 12 November 2012.

35. Pisabarro R, Irrazabal E, Recalde A. Primera encuesta nacional de sobrepeso y obesidad (ENSO I) [in Spanish]. Rev Med Urug. 2000;16:31–38.

36. Howard N, Archibald J, Ennis M, and the Caribbean Food and Nutrition Institute. *FAO – Nutrition Country Profiles: Guyana*. 2003; Available at: http://www.bvsde.paho.org/texcom/nutricion/guymap.pdf. Accessed 10 November 2012.

37. Figueredo R. Prevalencia de obesidad y distribución de la grasa corporal en una población urbana adulta de Paraguay. In: Braguinsky J, Alvarez Cordero R, Valenzuela A, eds. *Obesidad; un desafío para América Latina* [in Spanish]. Buenos Aires: El Ateneo; 2002.

38. Ennis M, and the Caribbean Food and Nutrition Institute. *FAO – Nutrition Country Profiles: Trinidad and Tobago*. 2003; Available at: http://www.bvsde.paho.org/texcom/nutricion/trimap.pdf. Accessed 10 November 2012.

39. Pisabarro R, Gutiérrez M, Bermúdez C, et al. Segunda Encuesta Nacional de Sobrepeso y Obesidad (ENSO 2) adultos (18–65 años o más) [in Spanish]. Rev Med Urug. 2009;25:14–26.

40. Braguinsky J, Sereday M, Cobeñas C, et al. Unexpected prevalence of obesity and associated metabolic risk factors in a medium size city (Venado Tuerto) of Argentina. Int J Obes Met Disord. 1998;22(Suppl 3):S215.

41. De Loredo L, Luquez H, Madoery R, et al. Hypertension prevalence in the Dean Funes Communitary Study. Hypertension. 1997;29:846.

42. Navarro A, Muñoz SE, Díaz MP, et al. Meat cooking habits and risk of colorectal cancer in Cordoba, Argentina. Nutrition. 2004;20:873–877.

43. Ros Pérez M, Medina-Gómez G. Obesity, adipogenesis and insulin resistance [in Spanish]. Endocrinol Nutr. 2011;58:360–369.

44. Das UN. Obesity: genes, brain, gut, and environment. Nutrition. 2010;26:459–473.

45. Tooke J. The association between insulin resistance and endotheliopathy. Diabetes Obes Metab. 1999;1(Suppl 1):17–22.

46. Dain A, Repossi G, Das UN, et al. Role of polyunsaturated fatty acids, the precursors of endocannabinoids, in human obesity and diabetes development. Front Biosci. 2010;2:1432–1447.

47. Das UN, Repossi G, Dain A, et al. L-arginine, nitric oxide and asymmetrical dimethylarginine in hypertension and type 2 diabetes mellitus. Front Biosci. 2011;16:13–20.

48. Miranda Garduño L, Reza Albarrán A. Obesidad, inflamación y diabetes [in Spanish]. Gac Med Mex. 2008;144:39–46.

49. Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346.

50. Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab. 2011;22:353–363.

51. Das UN, Repossi G, Dain A, et al. Is insulin resistance a disorder of the brain? Front Biosci. 2011;16:1–12.

52. Das UN, Puskás LG. Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders. Lipids Health Dis. 2009;8:61–72.

53. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. Circulation. 2003;107:1448–1453.

54. Golay A, Munger R, Felber JP. Obesity and NIDDM: the retrograde regulation concept. Diabetes Rev. 1997;5:69–82.

55. Das UN. Interaction(s) of polyunsaturated fatty acids with dietary protein and its relationship to the pathogenesis of hypertension. Am J Hypertens. 2010; 23:111–112.

56. Escobedo J, Schargrodsky H, Champagne B, et al. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol. 2009;8:52–60.

57. Luquez H, De Loredo L, Madoery RJ, et al. Síndrome metabólico: prevalencia en dos comunidades de Córdoba, Argentina, de acuerdo con definiciones ATP-III y OMS [in Spanish]. Rev Fed Arg Cardiol. 2005;34:80–95.

58. Sempértegui F, Estrella B, Tucker KL, et al. Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. Public Health Nutr. 2011;14:758–767.

59. Ryder E, Silva E, Sulbarán T, et al. Black Hispanics have a worse cardiovascular risk profile than mixed Hispanics in Venezuela. Invest Clin. 2007;48:45–55.

60. Bustos P, da Silva AA, Amigo H, et al. Metabolic syndrome in young adults from two socioeconomic Latin American settings. Nutr Metab Cardiovasc Dis. 2007; 17:581–589.

61. Cárdenas Quintana H, Sánchez Abanto J, Roldán Arbieto L, et al. Prevalence of metabolic syndrome in people 20 years old and more. Peru, 2005 [in Spanish]. Rev Esp Salud Publica. 2009;83:257–265.

62. Mujica V, Leiva E, Icaza G, et al. Evaluation of metabolic syndrome in adults of Talca city, Chile. Nutr J. 2008;15:14–20.

63. De Loredo L, Steinacher M, Carri D, et al. Prevalence of insulin resistance and its association with type 2 diabetes and other cardiovascular risk factors. Rev Fac Cienc Med Cordoba. 2004;61(Suppl):26–37.

64. Figueiredo Neto JA, Figuerêdo ED, Barbosa JB, et al. Metabolic syndrome and menopause: cross-sectional study in gynecology clinic. Arq Bras Cardiol. 2010; 95:339–345.

65. Ezenwaka CE, Nwagbara E, Seales D, et al. A comparative study of the prevalence of the metabolic syndrome and its components in type 2 diabetic patients in two Caribbean islands using the new International Diabetes Federation definition. Arch Physiol Biochem. 2007;113:202–210.

66. Hidalgo LA, Chedraui PA, Morocho N, et al. The metabolic syndrome among postmenopausal women in Ecuador. Gynecol Endocrinol. 2006;22:447–454.

67. Soutelo J, Saban M, Quevedo V, et al. Metabolic syndrome in Argentine women: ATPIII, IDF, IDF/AHA/NHLBI; what criterion should be used? Gynecol Endocrinol. 2011;27:448–451.

68. Howard B. Obesidad y metabolismo de las lipoproteínas: relación con la enfermedad cardiovascular [in Spanish]. In: Fletcher G, Grundy S, Hayman L, eds. *Obesidad: Impacto en la Enfermedad Cardiovascular. American Heart Association monograph series*, 1st ed. Buenos Aires: American Heart Association; 2001:157–169.

69. Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 1990;10:497–511.

70. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102:179–184.

71. Castelli W. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76:4–12.

72. Kinney BP, Qiao L, Levaugh JM, et al. B56 alpha/protein phosphatase 2A inhibits adipose lipolysis in high-fat diet-induced obese mice. Endocrinology. 2010;151:3624–3632.

73. Garg A, Helderman JH, Koffler M, et al. Relationship between lipoprotein levels and in vivo insulin action in normal young white men. Metabolism. 1988;37:982–987.

74. Egusa G, Beltz WF, Grundy SM, et al. The influence of obesity on the metabolism of apolipoprotein B in men. J Clin Invest. 1985;76:596–603.

75. Kuller L. Epidemiología de la obesidad en los adultos en relación con la enfermedad cardiovascular [in Spanish]. In: Fletcher G, Grundy M, Hayman L, eds. *Obesidad: Impacto en la Enfermedad Cardiovascular. American Heart Association monograph series*, 1st ed. Buenos Aires: American Heart Association; 2001:3–32.

76. National Institutes of Health. *Atherosclerosis*. 2012; Available at: http://www.nlm.nih.gov/medlineplus/atherosclerosis.html. Accessed 31 October 2012.

77. Tribble D, Krauss R. Enfermedad cardiovascular ateroesclerótica [in Spanish]. In: Bowman B, Russell R, eds. *Conocimientos Actuales Sobre Nutrición*. 8th ed. Washington, DC: Organización Panamericana de la Salud and the International Life Sciences Institute. Publicación Científica y Técnica N°592, 2003:592–601.

78. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. News Physiol Sci. 1996;11:255–261.

79. Rocchini AP. The influence of obesity in hypertension. News Physiol Sci. 1990; 5:254–249.

80. Jones DW, Kim JS, Andrew ME, et al. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens. 1994;12:1433–1437.

81. Fiore MC, Jimenez PM, Cremonezzi D, et al. Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake. Am J Physiol Renal Physiol. 2011;301:F263–F270.

82. Yepez R. Obesidad [in Spanish]. In: Organización Panamericana de la Salud (OPS/OMS), ed. *Equidad en la mira: la salud pública en ecuador durante las últimas décadas*. Quito, Ecuador: Consejo Nacional de la Salud (CONASA); 2007:74–86.

83. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25–26 August 2002, Washington, DC. Diabetes Care. 2003;26:933–939.

84. Sowers KM, Sowers JR. Obesity, hypertension, and vascular disease. Curr Hypertens Rep. 1999;1:140–144.

85. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785–1788.

86. Mujica V, Urzúa A, Leiva E, et al. Intervention with education and exercise reverses the metabolic syndrome in adults. J Am Soc Hypertens. 2010;4:148–153.

87. Lino MZ, Muniz PT, Siqueira KS. Prevalence of overweight and associated factors in adults: a population survey in Rio Branco, Acre State, Brazil, 2007–2008. Cad Saúde Pública (Rio de Janeiro). 2011;27:797–810.

88. Das UN. *Metabolic Syndrome Pathophysiology: The Role of Essential Fatty Acids*, 1st ed. Ames, IA: Wiley Blackwell; 2010.

89. Hausberg M, Mark AL, Hoffman RP, et al. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens. 1995;13:1015–1021.

90. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006;29:81–90.

91. Rahmouni K, Correia MLG, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9–14.

92. Jahangir E, Comandé D, Rubinstein A. Cardiovascular disease research in Latin America: a comparative bibliometric analysis. World J Cardiol. 2011;3:383–387.

93. Pan American Health Organization/World Health Organization. *2010 Basic Country Health Profiles for the Americas*. 2010; Available at: http://www.paho.org/English/DD/AIS/cp_index.htm. Accessed 31 October 2012.

94. Rodríguez T, Malvezzi M, Chatenoud L, et al. Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970–2000. Heart 2006; 92:453–460.

95. Oviedo G, Morón de Salim M, Solano L. Obesity anthropometrics indicators and the association with coronary ischemic disease. Nutr Hosp. 2006;21:694–698.

96. Ruiz-Fernández N, Espinoza M, Barrios E, et al. Cardiometabolic factors in a community located at Valencia City, Venezuela. Rev Salud Publica (Bogota). 2009;11:383–394.

97. Herrera VM, Casas JP, Miranda JJ, et al. Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease. Int J Obes (Lond). 2009;33:568–576.

98. Medina-Lezama J, Pastorius CA, Zea-Diaz H, et al. Optimal definitions for abdominal obesity and the metabolic syndrome in Andean Hispanics: the PREVENCION study. Diabetes Care. 2010;33:1385–1388.

99. Lizarzaburu JL, Palinkas LA. Immigration, acculturation, and risk factors for obesity and cardiovascular disease: a comparison between Latinos of Peruvian descent in Peru and in the United States. Ethn Dis. 2002;12:342–352.

100. Lindgärde F, Ercilla MB, Correa LR, et al. Body adiposity, insulin, and leptin in subgroups of Peruvian Amerindians. High Alt Med Biol. 2004;5:27–31.

101. Pereira JC, Barreto SM, Passos VMA. Perfil de risco cardiovascular e autoavaliação da saúde no Brasil: estudo de base populacional [in Portuguese]. Rev Panam Salud Publica. 2009;255:491–498.

102. Campana EM, Brandão AA, Pozzan R, et al. Blood pressure in young individuals as a cardiovascular risk marker. The Rio de Janeiro study. Arq Bras Cardiol. 2009;93:608–615, 657–665.

103. Longo GZ, Neves J, Luciano VM, et al. Prevalence of high blood pressure levels and associated factors among adults in Southern Brazil. Arq Bras Cardiol. 2009;93:387–394.

104. Barbosa JB, Silva AA, Santos AM, et al. Prevalence of arterial hypertension and associated factors in adults in São Luís, state of Maranhão. Arq Bras Cardiol. 2008;91:236–242.

105. Gulliford MC, Mahabir D, Rocke B. Socioeconomic inequality in blood pressure and its determinants: cross-sectional data from Trinidad and Tobago. J Hum Hypertens. 2004;18:61–70.

106. Díaz ME. Hypertension and obesity. J Hum Hypertens. 2002;16(Suppl 1):S18–S22.

107. Jiménez JT, Palacios M, Cañete F, et al. Prevalence of diabetes mellitus and associated cardiovascular risk factors in an adult urban population in Paraguay. Diabet Med. 1998;15:334–338.

108. Ramirez MO, Pino CT, Furiasse LV, et al. Paraguayan National Blood Pressure Study: prevalence of hypertension in the general population. J Hum Hypertens. 1995;9:891–897.

109. Fleischer NL, Diez Roux AV, Alazraqui M, et al. Social patterning of chronic disease risk factors in a Latin American city. J Urban Health 2008;85:923–927.

110. Rubinstein A, Colantonio L, Bardach A, et al. Estimación de la carga de las enfermedades cardiovasculares atribuible a factores de riesgo modificables en Argentina [in Spanish]. Rev Panam Salud Publica. 2010;27:237–245.

111. Rubinstein AL, Irazola VE, Poggio R, et al. Detection and follow-up of cardiovascular disease and risk factors in the Southern Cone of Latin America: the CESCAS I study. BMJ. 2011;1:e000126.

112. Krukowski RA, West DS. Consideration of the food environment in cancer risk reduction. J Am Diet Assoc. 2010;110:842–844.

113. World Cancer Research Foundation/American Institute for Cancer Research. *Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective*. 2007. Available at: http://www.dietandcancerreport.org/expert_report/report_contents/index.php. Accessed 10 November 2012.

114. Weinstein IB. The origins of human cancer: molecular mechanisms of carcinogenesis and their implication for cancer prevention and treatment – twenty-seventh GHA Clowes Memorial Award Lectures. Cancer Res. 1988;48:4135–4143.

115. Doll R, Peto R. The causes of cancer: quantitative estimate of available risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191–1308.

116. Pasqualini ME, Berra MA, Yurawecz MP, et al. Dietary manipulation of precursor polyunsaturated fatty acids modulates eicosanoid and endocanabinoid synthesis: a potential tool to control tumor development. Curr Nutr Food Sci. 2008;4:161–175.

117. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

118. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175–1183.

119. Comba A, Pasqualini ME. Primers on molecular pathways – lipoxygenases: their role as an oncogenic pathway in pancreatic cancer. Pancreatology. 2009;9:724–728.

120. Ray LB. Inflammation and tumor progression. Sci STKE. 2007;394:tw246.

121. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.

122. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217–226.

123. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest. 2007;117:60–69.

124. Dobrovolskaia MA, Kozlov SV. Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets. 2005;5:325–344.

125. Das UN. Clinical laboratory tools to diagnose inflammation. Adv Clin Chem. 2001;41:189–229.

126. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit. 2007;13:RA 214–RA 221.

127. Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1–14.

128. Ye J, Keller JN. Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction. Aging. 2010;2:361–368.

129. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132:259–272.

130. Court N, Vasseur V, Vacher R, et al. Partial redundancy of the pattern recognition receptors, scavenger receptors, and C-type lectins for the long-term control of *Mycobacterium tuberculosis* infection. J Immunol. 2010;184:7057–7070.

131. Das UN. Can essential fatty acids reduce the burden of disease(s)? Lipids Health Dis. 2008;7:9–13.

132. Oxenkrug GF. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci. 2010;46:56–63.

133. Karin M, Greten FR. NF-kB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–759.

134. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–436.

135. Comba A, Maestri DM, Berra MA, et al. Effect of ω-3 and ω-9 fatty acid rich oils on lipoxygenases and cyclooxygenases enzymes and on the growth of a mammary adenocarcinoma model. Lipids Health Dis. 2010;9:112–123.

136. Pradhan M, Bembinster LA, Baumgarten SC, et al. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NFNB cooperativity at adjacent response elements. J Biol Chem. 2010;285:31100–31106.

137. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545.

138. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52.

139. Micić D, Polovina S. Obesity and coronary heart disease: the mechanism of atherogenic impact [in Serbian]. Med Pregl. 2009;62 (Suppl 3):S43–S46.

140. Eynard AR, Jiang WG, Mansel RE. Eicosatrienoic acid (20:3 n-9) inhibits the expression of E-cadherin and desmoglein in human squamous cell carcinoma in vitro. Prostaglandins Leukot Essent Fatty Acids. 1998;59:371–377.

141. Thorand B, Zierer A, Baumert J, et al. Associations between leptin and the leptin/adiponectin ratio and incident type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984–2002. Diabet Med. 2010;27:1004–1011.

142. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501.

143. Botey Puig A, Coca Payeras A, de la Sierra Iserte A. Hipertensión Arterial [in Spanish]. In: Farrera P, Rozman C, eds. Medicina Interna, 15th ed. Madrid: Elsevier; 2006:587–609.

144. Kishimoto T. Interleukin-6: from basic science to medicine – 40 years in immunology. Annu Rev Immunol. 2005;23:1–21.

145. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–124.

146. Wei LH, Kuo ML, Chen CA, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene. 2001;20:5799–5809.

147. Drachenberg DE, Elgamal AA, Rowbotham R, et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999;41:127–133.

148. Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161:182–187.

149. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest. 2007;117:3660–3663.

150. Twillie DA, Eisenberger MA, Carducci MA, et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995;43:542–549.

151. Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007;9:R32.

152. Aleksic T, Chitnis MM, Perestenko OV, et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res. 2010;70:6412–6419.

153. Walker MP, Diaugustine RP, Zeringue E, et al. An IGF1/insulin receptor substrate-1 pathway stimulates a mitotic kinase (cdk1) in the uterine epithelium during the proliferative response to estradiol. J Endocrinol. 2010;207:225–235.

154. Denis G, Arruda AP, Romanatto T, et al. TNF-alpha transiently induces endoplasmic reticulum stress and an incomplete unfolded protein response in the hypothalamus. Neuroscience. 2010;170:1035–1044.

155. Das UN. Gamma-linolenic acid therapy of human glioma – a review of in vitro, in vivo, and clinical studies. Med Sci Monit. 2007;13:RA119–RA131.

156. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688–1894.

157. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCON 2008. Int J Cancer. 2010;127:2893–2917.

158. Niclis C, Díaz MP, La Vecchia C. Breast cancer mortality trends and patterns in Córdoba, Argentina in the period 1986–2006. Eur J Cancer Prev. 2010;19:94–99.

159. Niclis C, Pou SA, Bengió RH, et al. Prostate cancer mortality trends in Argentina 1986–2006: an age-period-cohort and joinpoint analysis. Cad Saude Publica. 2011;27:123–130.

160. Pou SA, Osella AR, Eynard AR, et al. Colorectal cancer mortality trends in Córdoba, Argentina. Cancer Epidemiol. 2009;33:406–412.

161. Pou SA, Osella AR, Eynard AR, et al. Cancer mortality in Córdoba, Argentina, 1986–2006: an age-period-cohort analysis. Tumori. 2010;96:202–212.

162. Pou SA, Osella AR, Diaz MP. Bladder cancer mortality trends and patterns in Córdoba, Argentina (1986–2006). Cancer Causes Control. 2011;22:407–415.

163. Díaz MP, Osella AR, Aballay LR, et al. Cancer incidence pattern in Cordoba, Argentina. Eur J Cancer Prev. 2009;18:259–266.

164. Diaz MP, Corrente JE, Osella AR, et al. Modelling spatial distribution of cancer incidence in Cordoba, Argentina. Appl Cancer Res. 2010;30:12–25.

165. Lantieri MJ, Butinof M, Fernández RA, et al. Work practices, exposure assessment and geographical analysis of pesticide applicators in Argentina. In: Stoytcheva M, ed. Pesticides in the Modern World – Effects of Pesticides Exposure. Rijeka, Croatia: InTech Europe; 2011:115–138.

166. Gil Montero R, Teruel A, Massé G, et al. Capítulo Argentina y Uruguay en los albores del siglo XX.Heterogeneidades nacionales y homogeneidades transnacionales. Aportes demográficos para su interpretación [in Spanish]. In: Celton, D, Miro C, Sánchez Albornoz N, eds. Cambios demográficos en América latina: la experiencia de cinco siglos. Córdoba, Argentina: Universidad Nacional de Córdoba and Internatial Union for Scientific Study of Population; 1998:607–640.

167. Navarro A, Muñoz SE, Eynard AR. Diet, feeding habits and risk of colorectal cancer in Córdoba. Argentina. A pilot study. J Exp Clin Cancer Res. 1995;14:287–291.

168. Navarro A, Osella AR, Muñoz SE, et al. Fatty acids, fibres and colorectal cancer risk in Córdoba, Argentina. J Epidemiol Biostat. 1998;3:415–422.

169. Navarro A, Osella AR, Muñoz SE, et al. Fibres, dietary lipids and colorectal cáncer risk in Córdoba, Argentina. J Epidemiol Biostat. 1998;3:415–423.

170. Navarro A, Diaz MP, Muñoz SE, et al. Characterisation of meat consumption and risk of colorectal cancer in Cordoba, Argentina. Nutrition. 2003;19:7–10.

171. Pou SA, Díaz MD, Osella AR. Applying multilevel model to the relationship of dietary patterns and colorectal cancer: an ongoing case-control study in Córdoba, Argentina. Eur J Nutr. 2012;51:755–764.

172. De Stefani E, Fierro L, Mendilaharsu M, et al. Meat intake, "mate" drinking and renal cell cancer in Uruguay: a case-control study. Br J Cancer. 1998;78:1239–1243.

173. Solimano G, Mazzei M. Which are the causes of death among Chileans today? Long-term perspectives. Rev Med Chil. 2007;135:932–938.

174. Atalah E, Urteaga C, Rebolledo A, et al. Breast cancer risk factors in women in Santiago, Chile. Rev Med Chil. 2000;128:137–143.

175. Ronco AL, Boeing H, De Stefani E, et al. A case-control study on fat-to-muscle ratio and risk of breast cancer. Nutr Cancer. 2009;61:466–474.

176. Ronco AL, Mendoza B, Varas X, et al. Somatotype and risk of breast cancer: a case-control study in Uruguay. Rev Bras Epidemiol. 2008;11:215–227.

177. Iscovich JM, Iscovich RB, Howe G, et al. A case-control study of diet and breast cancer in Argentina. Int J Cancer. 1989;44:770–776.

178. Pathak DR, Whittemore AS. Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol. 1992;135:153–168.

179. Niclis C, Díaz MP, Eynard AR, et al. Dietary habits and prostate cancer prevention: a review of observational studies by focusing on South America. Nutr Cancer. 2012;64:23–33.

180. López Fontana C, Maselli Artola ME, Vanrell Rodríguez MC, et al. Advances on the influence of adipose tissue on prostate cancer. Actas Urol Esp. 2009;33:242–248.

181. Negrón R, Vásquez A, Nieves M, et al. Body mass index affects the diagnosis and progression of prostate cancer in Hispanics. Ethn Dis. 2010;20(Suppl 1):S1–168–S172.

182. Iscovich JM, L'Abbé KA, Castelleto R, et al. Colon cancer in Argentina. I: risk from intake of dietary items. Int J Cancer. 1992;51:851–857.

183. Iscovich JM, L'Abbé KA, Castelleto R, et al. Colon cancer in Argentina. II: risk from fibre, fat and nutrients. Int J Cancer. 1992;51:858–861.

184. Andreatta MM, Muñoz SE, Lantieri MJ, et al. Artificial sweetener consumption and urinary tract tumors in Cordoba, Argentina. Prev Med. 2008;47:136–139.

185. Andreatta MM, Navarro A, Muñoz SE, et al. Dietary patterns and food groups are linked to the risk of urinary tract tumors in Argentina. Eur J Cancer Prev. 2010;19:478–484.

186. Villavicencio A, Aguilar G, Argüello G, et al. The effect of overweight and obesity on proliferation and activation of AKT and ERK in human endometria. Gynecol Oncol. 2010;117:96–102.